CHARLOTTESVILLE, VA – Wednesday, January 6, 2010 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that David R. Jones, M.D., has joined its staff as Chief Medical Officer and member of its Scientific Advisory Board (SAB). In addition, Guy M. Chisolm, Ph.D., [...]

CHARLOTTESVILLE, VA – Tuesday, June 10, 2008 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of life-threatening unmet medical needs, today announced the addition of Mark T. Giles to its Board of Directors. Mr. Giles is the Chairman of the Board of Virginia National Bank in Charlottesville, Virginia. He [...]

CHARLOTTESVILLE, VA – April 26, 2007 – Diffusion Pharmaceuticals LLC, a clinical-stage drug discovery and development company pioneering a revolutionary approach to the treatment of life-threatening diseases, today announced that it has formed a Scientific Advisory Board (SAB) to advise the Company on its clinical development programs. The SAB, comprised of four noted scientists and [...]

CHARLOTTESVILLE, VA –Tuesday, February 3, 2004 — Diffusion Pharmaceuticals LLC, a drug-development company commercializing its novel small-molecule drug, trans sodium crocetinate (TSC), announced that David G. Kalergis, JD/MBA, joined the company as Chief Executive Officer, effective January 25, 2004. Mr. Kalergis will report to Diffusion Pharmaceuticals’ Board of Directors. The company also announced that Dr. [...]